Core Viewpoint - Precore Gold Corp. has accelerated its acquisition of the Lac Big-Rush Gold Property to immediately own 100% of it, modifying the original three-year agreement due to the property's discovery potential in a prolific mining camp [1][2]. Company Developments - The acquisition of the Lac Big-Rush Property includes an additional 498 hectares, bringing the total to 49 claims covering 2,712 hectares in the Chibougamau mining camp [5]. - The final terms of the transaction involve a cash payment of $20,000 and the issuance of 250,000 common shares, with the vendor retaining a 2% Net Smelter Royalty (NSR) [10][11]. Industry Context - The acquisition follows a significant M&A transaction in the region, where Iamgold Corporation acquired Northern Superior Resources Inc., creating the Nelligan Mining Complex, which has Measured & Indicated Mineral Resources of 3.75 million ounces of gold and Inferred Mineral Resources of 8.65 million ounces [3]. - Precore Gold's property is strategically located near Iamgold's Croteau Project, which has an Inferred resource of 640,000 ounces at 1.73 g/t, just 300 meters from Precore's boundaries [4]. Future Plans - The company plans to initiate a preliminary exploration campaign in the second half of 2026, leveraging historical drill hole data that has not been explored since the early 1980s [9].

Core Viewpoint - Jyske Realkredit A/S has published Supplement no. 1 to its Base Prospectus dated June 27, 2025, concerning covered bonds, mortgage bonds, and bonds issued under the Danish Mortgage-Credit Loans and Mortgage-Credit Bonds Act [1]. Group 1 - The Supplement no. 1 is available for download in both Danish and English on Jyske Realkredit's official website [2]. - In case of discrepancies between the Danish text and the English translation, the Danish text will prevail [2]. - The announcement includes contact information for further inquiries, specifically mentioning the Head of Rating and IR and Legal Counsel [4].

Core Viewpoint - GE Medical Holding AB has exercised all its warrants in EXACT Therapeutics, resulting in gross proceeds of NOK 33 million, following a positive safety read-out from the phase 2 ENACT trial in locally advanced pancreatic cancer [1][2]. Group 1: Company Developments - EXACT Therapeutics announced that GE Medical Holding AB will exercise all of its 26,973,169 warrants, leading to gross proceeds of NOK 33 million for the company [2]. - The exercise of warrants is linked to the positive safety read-out from the ENACT phase 2 trial, which has encouraged further investment [2][5]. - The remaining warrant holders have until 26 February 2026 to exercise their warrants, with updates on the exercise expected to follow [2]. Group 2: Clinical Trial Insights - The ENACT phase 2 trial has shown early encouraging results, including significant tumor shrinkage and a decrease in the tumor biomarker CA 19-9 by over 85% [5]. - The Trial Monitoring Committee has issued a positive conclusion for the pre-planned safety read-out, allowing the trial to proceed as planned [5]. Group 3: Company Background - EXACT Therapeutics is a clinical-stage precision medicine company that utilizes ultrasound to activate its proprietary drug PS101, enhancing the clinical benefits of oncology therapies [4]. - PS101 has a unique mode of action and can be combined with various therapeutic agents across multiple indications, including brain diseases [4].

Core Insights - Ontex Group NV has launched a new adult incontinence product range called Sensitive, designed to provide superior protection while being gentle on the skin [1][3]. Product Development - The Sensitive range includes three products: Sensitive Pants, Sensitive Slip, and Sensitive Form, which will be gradually available to healthcare institutions across Europe [1]. - The new products incorporate innovative features such as a topsheet enriched with botanical ingredients to prevent skin irritation, innovative Y-core technology for instant dryness, and faster absorption capabilities—up to 2.5 times faster than previous products [7]. Market Research Findings - Recent research by Ontex involving over 2,500 individuals with incontinence revealed that nearly 50% have experienced dermatitis or skin irritation, significantly impacting their daily lives [2]. - Approximately 80% of caregivers lack training to recognize dermatitis, highlighting the need for better education and product design to prevent complications [2]. Educational Initiatives - To address the educational gap, Ontex provides expert training on recognizing, preventing, and treating dermatitis related to incontinence through its network of nurse advisors and the Ontex Academy online platform [4]. Company Overview - Ontex is a leading international developer and producer of personal care products, including baby care, feminine care, and adult care, primarily operating in Europe and North America [8]. - The company employs around 5,100 people and has a presence in 11 countries, with its products distributed in approximately 100 countries [8].

Group 1 - International Petroleum Corporation (IPC) has received approval from the Swedish Financial Supervisory Authority for the prospectus related to the listing of its USD 450 million 7.50 percent senior unsecured bonds on Euronext Oslo Børs, with trading expected to commence around February 6, 2026 [1][2]. - The senior unsecured bonds were originally issued on October 10, 2025, and will mature in October 2030 [2]. - IPC is an international oil and gas exploration and production company with a portfolio of assets in Canada, Malaysia, and France, positioning the company for both organic and inorganic growth [3].

Core Viewpoint - International Petroleum Corporation (IPC) has received approval from the Swedish Financial Supervisory Authority for the prospectus related to the listing of its USD 450 million senior unsecured bonds on Euronext Oslo Børs, with trading expected to commence around February 6, 2026 [1][2]. Group 1: Bond Details - IPC's senior unsecured bonds were issued on October 10, 2025, with a maturity date set for October 2030 [2]. - The bonds carry an interest rate of 7.50 percent [1]. Group 2: Company Overview - IPC is an international oil and gas exploration and production company with a portfolio of assets located in Canada, Malaysia, and France, which supports both organic and inorganic growth [3]. - IPC is part of the Lundin Group of Companies and is incorporated in Canada, with shares listed on the Toronto Stock Exchange (TSX) and Nasdaq Stockholm under the symbol "IPCO" [3].

Core Viewpoint - Pony AI Inc. is set to hold an extraordinary general meeting (EGM) on April 2, 2026, to consider and potentially pass proposed resolutions supported by the board of directors [1]. Group 1: Extraordinary General Meeting (EGM) - The EGM will take place at 11:00 a.m. Beijing time on April 2, 2026, at Datang Industrial Park, Guangzhou, China [1]. - The EGM will follow class meetings for holders of Class A and Class B ordinary shares, which will also occur on the same date and location [2]. - Shareholders and holders of American depositary shares (ADSs) are encouraged to vote in favor of the proposed resolutions [1]. Group 2: Voting Eligibility - Holders of record of the Company's ordinary shares as of February 27, 2026, are entitled to attend and vote at the EGM and the class meetings [3]. - ADS holders must provide voting instructions to Deutsche Bank Trust Company Americas to exercise their voting rights for Class A ordinary shares [3]. Group 3: Company Overview - Pony AI Inc., founded in 2016, is a leader in the mass production and commercialization of autonomous driving technology [4]. - The company focuses on delivering safe and reliable autonomous driving solutions, powered by its proprietary technologies [4]. - Pony AI operates globally, with a vision of "Autonomous Mobility Everywhere," and has established extensive partnerships across the autonomous driving value chain [4].

Company Overview - Vistin Pharma ASA is a Norwegian pharmaceutical company specializing in the production of Metformin Hydrochloride (API) and Direct Compressible lubricated granules [2] - The company is a dedicated European Metformin producer, positioning itself as a key supplier to leading pharmaceutical companies [2] - Vistin Pharma is headquartered in Oslo, Norway, and operates a dedicated manufacturing facility in Kragerø with a team of highly qualified employees [2] Upcoming Financial Results - Vistin Pharma will release its fourth quarter and preliminary 2025 results on February 12, 2025 [1] - A conference call for shareholders and interested parties will take place on the same day at 08:30 CET, including a Q&A session following the management discussion [1] - The conference call will be conducted in English and will be accessible via web and audio [1]

Core Viewpoint - Wolters Kluwer has repurchased 177,617 ordinary shares for €13.5 million at an average price of €76.20 during the period from January 29 to February 4, 2026, as part of its ongoing share buyback program [1][2]. Share Buyback Program - The share buyback program was announced on November 5, 2025, with a total repurchase target of up to €200 million from November 6, 2025, to February 23, 2026 [2]. - As of the current date in 2026, a total of 768,304 shares have been repurchased for a total consideration of €64.8 million, with an average share price of €84.34 [2]. Treasury Shares - The repurchased shares are held as treasury shares and will be utilized for capital reduction through share cancellation [3]. Company Overview - Wolters Kluwer is a global leader in professional information solutions, software, and services, serving customers in over 180 countries and employing approximately 21,900 people [4][5]. - The company reported annual revenues of €5.9 billion for 2024 and is headquartered in Alphen aan den Rijn, the Netherlands [5].

Core Insights - Changan Automobile has launched its global sodium-ion battery strategy and commenced the 2026 Global Testing Season in Yakeshi, Inner Mongolia [1][3] Group 1: Sodium-Ion Battery Technology - Changan is accelerating the development of sodium-ion battery technology as part of its global battery strategy, with plans to introduce new sodium-ion battery-equipped vehicles across multiple brands soon [3] - Sodium-ion battery systems have demonstrated stable discharge capabilities under extreme low temperatures, validated down to minus 40 degrees Celsius [4] Group 2: Safety and Testing - Changan and CATL conducted extreme abuse tests on sodium-ion batteries, exceeding national safety standards without incidents of fire, explosion, smoke, or thermal runaway [4] - The launch event showcased SDA Intelligence, which focuses on proactive, AI-driven vehicle stabilization, tested under severe low-temperature conditions [5] Group 3: Vehicle Performance - The AVATR 12 successfully completed an emergency lane change on ice at 80 km/h, while CHANGAN NEVO Q05 identified obstacles on low-friction ice during an Adaptive Cruise Control challenge [6] - CHANGAN DEEPAL L06 demonstrated rapid posture adjustments during a high-speed circular drift challenge on snow [6] Group 4: Global Testing Plans - The 2026 Global Testing Season will extend beyond Yakeshi, including high-humidity durability tests in Southeast Asia and high-altitude chassis tuning in the European Alps [8] - Winter testing in Eurasia will focus on ice and snow conditions, with the AVATR 12 as the test vehicle, while a cross-country drive in Mexico will assess long-distance reliability [9]